Allopurinol and Dabigatran etexilate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Allopurinol (allopurinol) and Dabigatran etexilate (dabigatran etexilate). Common drug interactions include abdominal pain upper among females and confusional state among males.

The phase IV clinical study analyzes what interactions people have when they take Allopurinol and Dabigatran etexilate. It is created by eHealthMe based on reports of 51 people who take the same drugs from the FDA, and is updated regularly.

What is Allopurinol?

Allopurinol has active ingredients of allopurinol. It is often used in gout. eHealthMe is studying from 190,868 Allopurinol users. Check the latest studies of Allopurinol.

What is Dabigatran etexilate?

Dabigatran etexilate has active ingredients of dabigatran etexilate. eHealthMe is studying from 908 Dabigatran etexilate users. Check the latest studies of Dabigatran etexilate.

On Jul, 16, 2026

51 people who take Allopurinol and Dabigatran etexilate together, and have interactions are studied.

Allopurinol and Dabigatran etexilate drug interactions.

What are the common drug interactions of Allopurinol and Dabigatran Etexilate, by gender? *:

female:

Abdominal pain upper
Arthralgia (joint pain)
Depression
Dysuria (painful or difficult urination)
Melaena (the passage of black, tarry stools)
Nausea (feeling of having an urge to vomit)
Hyperkalaemia (damage to or disease of the kidney)
Blood cholesterol decreased
Atrioventricular block first degree (heart block first degree)
Diabetes mellitus inadequate control

male:

Confusional state
Dysarthria (speech disorder)
Sepsis (a severe blood infection that can lead to organ failure and death)
Weight decreased
Abdominal pain lower
Altered state of consciousness (altered state of mind)
Bacteraemia (presence of bacteria in the blood)
Blood pressure increased
Cardiac arrest
Cerebral disorder (brain disease)

What are the common drug interactions of Allopurinol and Dabigatran Etexilate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Syncope (loss of consciousness with an inability to maintain postural tone)

60+:

Abdominal pain upper
Arthralgia (joint pain)
Diabetes mellitus inadequate control
Drug dependence
Fall
Mobility decreased (ability to move is reduced)
Initial insomnia (feeling of inadequate or poor-quality sleep)
Hypotension (abnormally low blood pressure)
Syncope (loss of consciousness with an inability to maintain postural tone)
Insomnia (sleeplessness)

What are the existing conditions these people have? *

High Blood Pressure: 16 people, 31.37%
Pain: 13 people, 25.49%
Constipation: 11 people, 21.57%
Depression: 11 people, 21.57%
Type 2 Diabetes: 10 people, 19.61%
Chest Pain: 9 people, 17.65%
Cardiac Failure: 8 people, 15.69%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 5 people, 9.80%
Dizziness: 5 people, 9.80%
Diabetes: 4 people, 7.84%

* Approximation only. Some reports may have incomplete information.

Do you take Allopurinol and Dabigatran etexilate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously